NCT Number: NCT02203487
Safety, Tolerability and Pharmacokinetics of Increasing Repeated Doses of BIIF 1149 BS in Healthy Male Volunteers
The objective of the present study was to obtain information about the safety and tolerability of BIIF 1149 BS after repeated dosing and to obtain preliminary pharmacokinetics data (steady state and accumulation factor)
Looking for future studies?
Notify MeKey information
Conditions
Age range
21 year–50 year
Sex eligibility
Male
Study type
Interventional
Phase
Phase 1
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Participants should be healthy males
- Age range from 21 to 50 years
- Within +- 20% of their normal weight (Broca-Index)
- In accordance with Good Clinical Practice (GCP) and local legislation each volunteers are supposed to give their written informed consent prior to admission to the study
- Each subject will have his medical history taken and will receive a complete medical examination (incl. demographics, medical history, check of inclusion/exclusion criteria, physical examination, vital signs, 12-lead Electrocardiogram (ECG)
- Haematopoietic, hepatic and renal function test will be carried out in the laboratory
- The subjects will fast for 12 hours before collection of specimens for all laboratory evaluations. The above mentioned examinations will be performed within 14 days before the first administration of the test substance
Exclusion criteria
- Volunteers will be excluded from the study if the results of the medical examination or laboratory tests are judged by the clinical investigator to differ significantly from normal clinical values
- Volunteers with known gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Volunteers with diseases of the central nervous system (such as epilepsy) or with psychiatric disorders
- History of orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- Intake of a drug with a long half-life (>= 24 hours) within ten half-lives of the respective drug before enrolment in the study
- Use of any other drugs which might influence the results of the trial during the week previous to the start of the study
- Participation in another study with an investigational drug within the last two months preceding this study
- Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day)
- Inability to refrain from smoking on study days
- Alcohol abuse (> 40g/day)
- Drug abuse
- Blood donation (>= 100 ml) within the last 4 weeks
- Excessive physical activities (e.g. competitive sports) within the last week before the study
Treatment and study plan
Placebo
DrugPrimary outcomes
-
Number of subjects with adverse events
Time frame: up to 55 days
-
Number of subjects with abnormal changes in laboratory parameters
Time frame: up to 8 days after last blood sample
-
Number of subjects with clinically significant changes in vital signs (blood pressure, pulse rate)
Time frame: up to 8 days after last blood sample
Secondary outcomes
-
Number of subjects with clinically significant changes in 12-lead Electrocardiogram (ECG)
Time frame: up to 8 days after last blood sample
-
Cmax (Maximum concentration of the analyte in plasma)
Time frame: up to 360 hours after last drug administration
-
Tmax (Time to maximum observed concentration of the analyte in plasma)
Time frame: up to 360 hours after last drug administration
-
AUC (Area under the concentration-time curve of the analyte in plasma)
Time frame: up to 360 hours after last drug administration
-
Ae (Urinary excretion of parent drug)
Time frame: up to 120 hours after last drug administration
-
Cmin,ss (Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)
Time frame: after 24 hours of drug administration on day 9
-
MRT (Mean residence time of the analyte in the body)
Time frame: up to 360 hours after last drug administration
-
t½ (Terminal half-life of the analyte in plasma)
Time frame: up to 360 hours after last drug administration
-
Percent peak-trough fluctuation
Time frame: up to 360 hours after last drug administration
-
RA (AUC) Accumulation factor based on AUC-data
Time frame: up to 360 hours after last drug administration
-
RA (Ae) Accumulation factor based on Ae-data
Time frame: up to 120 hours after last drug administration
-
RA (Cmax) Accumulation factor based on Cmax -data
Time frame: up to 360 hours after drug administration on day 9
-
Cav (Average plasma concentration in a steady state interval)
Time frame: 24 hours after drug administration of day 9
Sponsors and collaborators
Lead sponsor
Boehringer Ingelheim
Industry
Registry information
Official study title
A Double-blind (Within Dose Groups), Randomised, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability and Preliminary Pharmacokinetics of Increasing Repeated Oral Doses (Nine Days Treatment of 5 mg and 10 mg and Eighteen Days Treatment of 25 mg and 40 mg) of BIIF 1149 BS in Healthy Male Volunteers
Important dates
- Study start
- 1999
- Primary completion
- 2000
- First posted
- Jul 30, 2014
- Registry last updated
- Jul 30, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Characterization of Gastric Evoked Potentials
NCT05924009
Healthy
Pittsburgh, Pennsylvania, United States
View Trial DetailsTo Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers
NCT07374406
Healthy
Jeonju, South Korea
View Trial DetailsDimensional Changes of the Keratinized Mucosa in Edentulous Ridges Following Accordian Technique Versus Conventional Free Gingival Grafts
NCT07365865
Deficient Keratinized Mucosa, Healthy
Cairo, Egypt
View Trial DetailsValidation of a Digital Twin Performing Strength Training
NCT04849923
Healthy
Winterthur, Canton of Zurich, Switzerland
View Trial Details